Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76,851,274
-
Total 13F shares
-
72,058,517
-
Share change
-
+9,933,060
-
Total reported value
-
$3,319,081,625
-
Put/Call ratio
-
81%
-
Price per share
-
$46.06
-
Number of holders
-
204
-
Value change
-
+$473,994,183
-
Number of buys
-
124
-
Number of sells
-
72
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2023
As of 31 Dec 2023,
Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by
204 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,058,517 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, FMR LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, WELLINGTON MANAGEMENT GROUP LLP, Polar Capital Holdings Plc, Capital World Investors, Capital International Investors, COMMODORE CAPITAL LP, Paradigm Biocapital Advisors LP, and BlackRock Inc..
This page lists
204
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.